Nisa Investment Advisors LLC Sells 4,028 Shares of Pfizer Inc. $PFE

Nisa Investment Advisors LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 0.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,366,264 shares of the biopharmaceutical company’s stock after selling 4,028 shares during the period. Nisa Investment Advisors LLC’s holdings in Pfizer were worth $33,118,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer during the first quarter worth about $27,000. Curio Wealth LLC grew its holdings in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the last quarter. North Capital Inc. purchased a new stake in Pfizer in the first quarter worth about $28,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the first quarter valued at approximately $28,000. Finally, Harbor Asset Planning Inc. purchased a new stake in shares of Pfizer in the second quarter worth $29,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup upped their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday. Finally, Bank of America lifted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Trading Up 0.5%

Shares of PFE opened at $24.79 on Friday. The company’s fifty day simple moving average is $24.87 and its 200-day simple moving average is $24.18. The company has a market cap of $140.92 billion, a P/E ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.17.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm earned $0.60 earnings per share. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.